Strategic vaccine focus Calder Biosciences is actively developing novel RSV and universal influenza vaccines using a nano-scale molecular engineering platform, presenting opportunities to partner on preclinical and clinical supply, manufacturing support, and early access to innovative vaccine candidates.

Clinical supply partnerships Recent and ongoing clinical supply agreements with Biodextris and Clean Biologics indicate strong interest from contract manufacturing and supply partners, suggesting a readiness to engage in co-development and scalable manufacturing partnerships.

Small team, high potential With a lean team of 2–10 employees, Calder presents a modular collaboration model where external CROs, CMOs, and strategic investors can play pivotal roles, enabling faster decision cycles and more flexible partnership structures.

Financial signal Reported revenue in the low to mid single digits indicates early-stage commercialization activity and potential for growth through milestone-driven collaborations, licensing deals, and contract manufacturing arrangements.

Technology and IP leverage The 3D-Vaxlock platform for protein subunit vaccine development positions Calder to attract partners seeking innovative vaccine technologies, potential co-development, or exclusive licensing opportunities aligned with multi-billion market opportunities.